ArticleBioMed research international2020
Independent Prognostic Potential of GNPNAT1 in Lung Adenocarcinoma.
Article in BioMed research international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 28 citations in OpenAlex.
- GNPNAT1 acts as a prognostic biomarker associated with immune infiltration in lung adenocarcinoma and promotes the proliferation and invasion of cancer cells.Discover oncology · 2025Article
- Integrated systems biology reveals an 8-gene signature predicting early-stage lung adenocarcinoma progression and patient survival.Scientific reports · 2025Article
- The role of B cell immunity in lung adenocarcinoma.Genes and immunity · 2025Review
- Multifaceted function of B cells in tumorigenesis.Frontiers of medicine · 2025Review
- GNPNAT1 Serves as a Prognostic Biomarker Correlated with Immune Infiltration and Promotes Cancer Cell Metastasis through Stabilization of Snai2 in Lung Adenocarcinoma.Biomedicines · 2024Article
- Construction of a prognostic model based on memory CD4+ T cell-associated genes for lung adenocarcinoma and its applications in immunotherapy.CPT: pharmacometrics & systems pharmacology · 2024Article
- Article
- GNPNAT1 promotes the stemness of breast cancer and serves as a potential prognostic biomarker.Oncology reports · 2023Article
- A novel cuproptosis-related signature predicts prognosis and immunotherapy efficacy in lung adenocarcinoma.American journal of translational research · 2023Article
- Prognosis and personalized treatment prediction in lung adenocarcinoma: AnFrontiers in pharmacology · 2023Article
- Glucosamine-phosphate N-acetyltransferase 1 and its DNA methylation can be biomarkers for the diagnosis and prognosis of lung cancer.Journal of clinical laboratory analysis · 2022Article
- Development of a metabolism-related signature for predicting prognosis, immune infiltration and immunotherapy response in breast cancer.American journal of cancer research · 2022Article
- Identification and validation of a novel phagocytosis regulators-related signature with potential prognostic and immunotherapeutic value in patients with lung adenocarcinoma.Frontiers in oncology · 2022Article
- Article
- Development of a 5-Gene Signature to Evaluate Lung Adenocarcinoma Prognosis Based on the Features of Cancer Stem Cells.BioMed research international · 2022Article
- A Distinct Glucose Metabolism Signature of Lung Adenocarcinoma With Prognostic Value.Frontiers in genetics · 2022Article
- Evaluating the Prognostic and Therapeutic Potentials of the Proteasome 26S Subunit, ATPase (Frontiers in genetics · 2022Article
- GNPNAT1 Predicts Poor Prognosis and Cancer Development in Non-Small Cell Lung Cancer.Cancer management and research · 2022Article
- XBP1 impacts lung adenocarcinoma progression by promoting plasma cell adaptation to the tumor microenvironment.Frontiers in genetics · 2022Article
- A Novel Approach for the Discovery of Biomarkers of Radiotherapy Response in Breast Cancer.Journal of personalized medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlucosamine-Phosphate N-Acetyltransferase 1 (GNPNAT1) is a critical enzyme in the biosynthesis of uridine diphosphate-N-acetylglucosamine. It has many important functions, such as protein binding, monosaccharide binding, and embryonic development and growth. However, the role of GNPNAT1 in lung adenocarcinoma (LUAD) remains unclear.
methodsIn this study, we explored the expression pattern and prognostic value of GNPNAT1 in LUAD across TCGA and GEO databases and assessed its independent prognostic value via Cox analysis. LinkedOmics and GEPIA2 were applied to investigate coexpression and functional networks associated with GNPNAT1. The TIMER web tool was deployed to assess the correlation between GNPNAT1 and the main six types of tumor-infiltrating immune cells. Besides, the correlations between GNPNAT1 and the LUAD common genetic mutations, TMB, and immune signatures were examined.
resultsGNPNAT1 was validated upregulated in tumor tissues in TCGA-LUAD and GEO cohorts. Moreover, in both TCGA and GEO cohorts, high GNPNAT1 expression was found to be associated with poor overall survival. Cox analysis showed that high GNPNAT1 expression was an independent risk factor for LUAD. Functional network analysis suggested that GNPNAT1 regulates cell cycle, ribosome, proteasome, RNA transport, and spliceosome signaling through pathways involving multiple cancer-related kinases and E2F family. In addition, GNPNAT1 correlated with infiltrating levels of B cells, CD4+ T cells, and dendritic cells. B cells and dendritic cells could predict the outcome of LUAD, and B cells and CD4+ T cells were significant independent risk factors. The TMB and mutations of KRAS, EGFR, STK11, and TP53 were correlated with GNPNAT1. At last, the correlation analysis showed GNPNAT1 correlated with most of the immune signatures we performed.
conclusionOur findings showed that GNPNAT1 was correlated to the prognosis and immune infiltration of LUAD. In particular, the tight relationship between GNPNAT1 and B cell marker genes may be the epicenter of the immune response and one of the key factors affecting the prognosis. Our findings laid the foundation for further research on the immunomodulatory role of GNPNAT1 in LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.